Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 197
Filtrar
2.
Br J Anaesth ; 125(3): 413-414, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32861405

RESUMEN

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief, Professor Hugh Hemmings, based on the recommendations of Justus-Liebig-University Giessen following an internal review of research conducted by Joachim Boldt at the University. This is further described in 'Further Retractions of Articles by Joachim Boldt', https://doi.org/10.1016/j.bja.2020.02.024.

3.
Br J Anaesth ; 125(3): 414, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32861407

RESUMEN

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief, Professor Hugh Hemmings, based on the recommendations of Justus-Liebig-University Giessen following an internal review of research conducted by Joachim Boldt at the University. This is further described in 'Further Retractions of Articles by Joachim Boldt', https://doi.org/10.1016/j.bja.2020.02.024.

4.
Br J Anaesth ; 125(3): 415, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32861408

RESUMEN

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief, Professor Hugh Hemmings, based on the recommendations of Justus-Liebig-University Giessen following an internal review of research conducted by Joachim Boldt at the University. This is further described in 'Further Retractions of Articles by Joachim Boldt', https://doi.org/10.1016/j.bja.2020.02.024.

5.
J Clin Pharmacol ; 58(10): 1284-1294, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29746722

RESUMEN

The aim of this work was to assess the relationship between the absolute lymphocyte count (ALC), and disability (as measured by the Expanded Disability Status Scale [EDSS]) and occurrence of relapses, 2 efficacy endpoints, respectively, in patients with remitting-relasping multiple sclerosis. Data for ALC, EDSS, and relapse rate were available from 1319 patients receiving placebo and/or cladribine tablets. Pharmacodynamic models were developed to characterize the time course of the endpoints. ALC-related measures were then evaluated as predictors of the efficacy endpoints. EDSS data were best fitted by a model where the logit-linear disease progression is affected by the dynamics of ALC change from baseline. Relapse rate data were best described by the Weibull hazard function, and the ALC change from baseline was also found to be a significant predictor of time to relapse. Presented models have shown that once cladribine exposure driven ALC-derived measures are included in the model, the need for drug effect components is of less importance (EDSS) or disappears (relapse rate). This simplifies the models and theoretically makes them mechanism specific rather than drug specific. Having a reliable mechanism-specific model would allow leveraging historical data across compounds, to support decision making in drug development and possibly shorten the time to market.


Asunto(s)
Evaluación de la Discapacidad , Inmunosupresores/uso terapéutico , Recuento de Linfocitos , Modelos Biológicos , Esclerosis Múltiple/tratamiento farmacológico , Adolescente , Adulto , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven
6.
Br J Anaesth ; 120(3): 469-474, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29452803

RESUMEN

The current guidelines for preoperative fasting recommend intervals of 6, 4, and 2 h (6-4-2) of fasting for solids, breast milk, and clear fluids, respectively. The objective is to minimize the risk of pulmonary aspiration of gastric contents, but also to prevent unnecessarily long fasting intervals. Pulmonary aspiration is rare and associated with nearly no mortality in paediatric anaesthesia. The incidence may have decreased during the last decades, judging from several audits published recently. However, several reports of very long fasting intervals have also been published, in spite of the implementation of the 6-4-2 fasting regimens. In this review, we examine the physiological basis for various fasting recommendations, the temporal relationship between fluid intake and residual gastric content, and the pathophysiological effects of preoperative fasting, and review recent publications of various attempts to reduce the incidence of prolonged fasting in children. The pros and cons of the current guidelines will be addressed, and possible strategies for a future revision will be suggested.


Asunto(s)
Ayuno , Complicaciones Intraoperatorias/prevención & control , Neumonía por Aspiración/prevención & control , Guías de Práctica Clínica como Asunto , Cuidados Preoperatorios/métodos , Niño , Contenido Digestivo , Humanos
7.
CPT Pharmacometrics Syst Pharmacol ; 6(6): 373-382, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28378918

RESUMEN

The relationships between exposure, biomarkers (vascular endothelial growth factor (VEGF), soluble VEGF receptors (sVEGFR)-1, -2, -3, and soluble stem cell factor receptor (sKIT)), tumor sum of longest diameters (SLD), diastolic blood pressure (dBP), and overall survival (OS) were investigated in a modeling framework. The dataset included 64 metastatic renal cell carcinoma patients (mRCC) treated with oral axitinib. Biomarker timecourses were described by indirect response (IDR) models where axitinib inhibits sVEGFR-1, -2, and -3 production, and VEGF degradation. No effect was identified on sKIT. A tumor model using sVEGFR-3 dynamics as driver predicted SLD data well. An IDR model, with axitinib exposure stimulating the response, characterized dBP increase. In a time-to-event model the SLD timecourse predicted OS better than exposure, biomarker- or dBP-related metrics. This type of framework can be used to relate pharmacokinetics, efficacy, and safety to long-term clinical outcome in mRCC patients treated with VEGFR inhibitors. (ClinicalTrial.gov identifier NCT00569946.).


Asunto(s)
Antineoplásicos , Carcinoma de Células Renales , Imidazoles , Indazoles , Neoplasias Renales , Modelos Biológicos , Inhibidores de Proteínas Quinasas , Antineoplásicos/efectos adversos , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Axitinib , Biomarcadores de Tumor/metabolismo , Presión Sanguínea/efectos de los fármacos , Carcinoma de Células Renales/tratamiento farmacológico , Carcinoma de Células Renales/metabolismo , Carcinoma de Células Renales/patología , Carcinoma de Células Renales/fisiopatología , Humanos , Imidazoles/efectos adversos , Imidazoles/uso terapéutico , Indazoles/efectos adversos , Indazoles/uso terapéutico , Estimación de Kaplan-Meier , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/metabolismo , Neoplasias Renales/patología , Neoplasias Renales/fisiopatología , Inhibidores de Proteínas Quinasas/efectos adversos , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas c-kit/metabolismo , Resultado del Tratamiento , Carga Tumoral , Factor A de Crecimiento Endotelial Vascular/metabolismo , Receptor 1 de Factores de Crecimiento Endotelial Vascular/metabolismo , Receptor 2 de Factores de Crecimiento Endotelial Vascular/metabolismo , Receptor 3 de Factores de Crecimiento Endotelial Vascular/metabolismo
8.
CPT Pharmacometrics Syst Pharmacol ; 6(7): 449-457, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28379635

RESUMEN

Three-dimensional and density-based tumor metrics have been suggested to better discriminate tumor response to treatment than unidimensional metrics, particularly for tumors exhibiting nonuniform size changes. In the developed pharmacometric modeling framework based on data from 77 imatinib-treated gastrointestinal patients, the time-courses of liver metastases' maximum transaxial diameters, software-calculated actual volumes (Vactual ) and calculated ellipsoidal volumes were characterized by logistic growth models, in which imatinib induced a linear dose-dependent size reduction. An indirect response model best described the reduction in density. Substantial interindividual variability in the drug effect of all response assessments and additional interlesion variability in the drug effect on density were identified. The predictive ability of longitudinal tumor unidimensional and three-dimensional size and density on overall survival (OS) and progression-free survival (PFS) were compared using parametric time-to-event models. Death hazard increased with increasing Vactual . This framework may guide early clinical interventions based on three-dimensional tumor responses to enhance benefits for patients with gastrointestinal stromal tumors (GIST).


Asunto(s)
Antineoplásicos/uso terapéutico , Tumores del Estroma Gastrointestinal , Mesilato de Imatinib/uso terapéutico , Neoplasias Hepáticas , Modelos Biológicos , Inhibidores de Proteínas Quinasas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Supervivencia sin Enfermedad , Femenino , Tumores del Estroma Gastrointestinal/diagnóstico por imagen , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Tumores del Estroma Gastrointestinal/patología , Humanos , Estimación de Kaplan-Meier , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Carga Tumoral
9.
Vox Sang ; 112(4): 379-387, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28271523

RESUMEN

BACKGROUND: Extracorporeal photopheresis (ECP) is an established treatment for graft-versus-host disease (GVHD). Various haematocrit thresholds have been used to trigger red blood cells transfusion prior to ECP. Moderate-to-severe GVHD is frequently complicated by anaemia; the safety and collection efficiency with a lower haematocrit for ECP is unknown. METHODS: We prospectively enrolled 26 consecutive adult GVHD patients with haematocrits between 25% and 28·9% who received ECP on the CELLEX system. Preprocedural transfusion was withheld. We monitored the adverse events and transfusions avoided. A complete blood cell count with differential was performed on preprocedural peripheral blood and buffy coat collected. Lymphocyte fold enrichment (LFE) was compared between this cohort and two historical control groups with haematocrits of 29% or higher. RESULTS: Red Blood Cells transfusion was avoided in the lower-haematocrit cohort without adverse events. The median LFE was 4·5 (95%CI, 3·1-5·7) in the lower-haematocrit cohort and 5·2 (95%CI, 4·1-6·5) in the higher-haematocrit CELLEX-treated control group. The median difference was 0·7 (95%CI, -0·3 to 2·0, P = 0·14). It could not be established that the lower-haematocrit cohort was non-inferior to the higher-haematocrit control group with a prespecified non-inferiority margin of 1·3. However, LFE was significantly higher in the lower-haematocrit cohort than the higher-haematocrit UVAR XTS-treated control group (P < 0·01). CONCLUSION: Buffy coat can be collected for ECP using CELLEX in GVHD patients with a haematocrit of 25% or higher, with a collection efficiency superior to that in patients with higher haematocrits but treated using UVAR XTS. No increase in adverse events was observed at these lower haematocrits.


Asunto(s)
Seguridad de la Sangre , Transfusión de Eritrocitos , Enfermedad Injerto contra Huésped/terapia , Fotoféresis , Adulto , Femenino , Enfermedad Injerto contra Huésped/sangre , Hematócrito , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven
10.
CPT Pharmacometrics Syst Pharmacol ; 5(4): 173-81, 2016 04.
Artículo en Inglés | MEDLINE | ID: mdl-27299707

RESUMEN

Pharmacometric models were developed to characterize the relationships between lesion-level tumor metabolic activity, as assessed by the maximum standardized uptake value (SUVmax) obtained on [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography (PET), tumor size, and overall survival (OS) in 66 patients with gastrointestinal stromal tumor (GIST) treated with intermittent sunitinib. An indirect response model in which sunitinib stimulates tumor loss best described the typically rapid decrease in SUVmax during on-treatment periods and the recovery during off-treatment periods. Substantial interindividual and interlesion variability were identified in SUVmax baseline and drug sensitivity. A parametric time-to-event model identified the relative change in SUVmax at one week for the lesion with the most pronounced response as a better predictor of OS than tumor size. Based on the proposed modeling framework, early changes in FDG-PET response may serve as predictor for long-term outcome in sunitinib-treated GIST.


Asunto(s)
Neoplasias Gastrointestinales/diagnóstico por imagen , Neoplasias Gastrointestinales/tratamiento farmacológico , Tumores del Estroma Gastrointestinal/diagnóstico por imagen , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Indoles/administración & dosificación , Indoles/farmacocinética , Pirroles/administración & dosificación , Pirroles/farmacocinética , Adulto , Fluorodesoxiglucosa F18 , Neoplasias Gastrointestinales/metabolismo , Tumores del Estroma Gastrointestinal/metabolismo , Humanos , Modelos Biológicos , Modelos Estadísticos , Dinámicas no Lineales , Tomografía de Emisión de Positrones/métodos , Radiofármacos , Sunitinib , Análisis de Supervivencia , Tasa de Supervivencia , Resultado del Tratamiento , Carga Tumoral
11.
Childs Nerv Syst ; 30(8): 1367-74, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24788567

RESUMEN

INTRODUCTION: Focal pressure-related changes in brain perfusion and metabolism are discussed in single-suture craniosynostosis and brachycephalic cases (bicoronal synostosis). Raised intracranial pressure levels could be measured in some cases. In order to find possible loco-regional brain tissue changes during plastic surgery, we investigated oxygenation and perfusion parameters using non-invasive near-infrared spectroscopy (NIRS) probes. METHODS: Twenty-two consecutively operated cases (mean age 7 months) with single-suture craniosynostosis were prospectively investigated using a NIRS probe (LEA(©), O2C, white light 500-800 nm, laser NIR). Measurements for oxygen saturation (SO(2)), relative quantity of hemoglobin (rHb), blood flow, and blood flow velocity of the bilateral frontal, temporal, and parietal cortices were taken transosseously (prior to decompression) and epidurally directly after decompression as well as 15 and 30 min after decompression and before closure. RESULTS: Twenty-two patients with scaphocephaly (11), trigonocephaly (6), anterior plagiocephaly (3), and brachycephaly (2) were investigated. SO(2) was improving in all patient subgroups, showing the highest levels in the fronto-temporal region; rHb improved in scaphocephalic, trigonocephalic, and brachycephalic children. Again, the highest values were found not only in the temporal but also in the frontal region and in brachycephalic patients also in the parietal cortex. CONCLUSION: These preliminary results of a new technology for brain tissue oxygenation and blood flow measurements suggest a regional compromise of cortical metabolism and circulation in patients with craniosynostosis.


Asunto(s)
Corteza Cerebral/metabolismo , Craneosinostosis/patología , Craneosinostosis/cirugía , Hemodinámica , Oxihemoglobinas/metabolismo , Procedimientos de Cirugía Plástica/métodos , Circulación Cerebrovascular/fisiología , Craneosinostosis/clasificación , Femenino , Humanos , Lactante , Masculino , Espectroscopía Infrarroja Corta
12.
Thorac Cardiovasc Surg ; 59(5): 268-73, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21557162

RESUMEN

BACKGROUND: The Aristotle score quantifies the complexity involved in congenital heart surgery. It defines surgical performance as complexity score times hospital survival. We studied how expected and observed surgical performance evolved over time. METHODS: 2312 main procedures carried out between 2006 and 2010 were analyzed. The Aristotle basic score, corresponding hospital survival and related observed surgical performance were estimated. Expected survival was based on the mortality risks published by O'Brien and coauthors. Observed performance divided by expected performance was called the standardized ratio of performance. This should trend towards a figure above 100%. Survival rates and performance are given with 95% confidence intervals. RESULTS: The mean Aristotle basic score was 7.88 ± 2.68. 51 patients died: observed hospital survival was 97.8 % (97.1 %-98.3%). 115 deaths were anticipated: expected survival was 95.2% (93.5%-96.3%). Observed and expected surgical performance reached 7.71 (7.65-7.75) and 7.49 (7.37-7.59), respectively. Therefore the overall standardized ratio of performance was 102.94%. The ratio increased from 2006 (ratio = 101.60%) to 2009 (103.92%) and was 103.42% in 2010. Performance was high for the repair of congenital corrected transposition of the great arteries and ventricular septal defect (VSD) by atrial switch and Rastelli procedure, the Norwood procedure, repair of truncus arteriosus, aortic arch repair and VSD closure, and the Ross-Konno procedure, with corresponding standardized ratios of 123.30%, 116.83%, 112.99%, 110.86% and 110.38%, respectively. With a ratio of 82.87%, performance was low for repair of Ebstein's anomaly. CONCLUSION: The standardized ratio of surgical performance integrates three factors into a single value: procedure complexity, postoperative observed survival, and comparison with expected survival. It constitutes an excellent instrument for quality monitoring of congenital heart surgery programs over time. It allows an accurate comparison of surgical performance across institutions with different case mixes.


Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Cardiopatías Congénitas/cirugía , Evaluación de Procesos y Resultados en Atención de Salud , Indicadores de Calidad de la Atención de Salud , Análisis de Varianza , Benchmarking , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Procedimientos Quirúrgicos Cardíacos/mortalidad , Competencia Clínica , Alemania , Cardiopatías Congénitas/mortalidad , Mortalidad Hospitalaria , Humanos , Evaluación de Procesos y Resultados en Atención de Salud/estadística & datos numéricos , Indicadores de Calidad de la Atención de Salud/estadística & datos numéricos , Medición de Riesgo , Factores de Riesgo , Tasa de Supervivencia , Factores de Tiempo , Resultado del Tratamiento
13.
Thorac Cardiovasc Surg ; 58(6): 322-7, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20824582

RESUMEN

BACKGROUND: Hospital costs are expected to correlate with clinical complexity. Do costs for congenital heart surgery correlate with Aristotle complexity scores? METHODS: 442 inpatient stays in 2008 were evaluated. Aristotle scores and levels were determined. Costs were estimated according to the German Institute for Hospital Reimbursement system. Pearson and Spearman R correlation coefficients and corresponding goodness-of-fit regression coefficients R2 were calculated. RESULTS: Mean basic and comprehensive Aristotle scores were 7.60 +/- 2.74 and 9.23 +/- 2.94 points, respectively. Mean expenses per hospital stay amounted to 29,369 +/- 30,823 Euros. Aristotle basic and comprehensive scores and levels were positively correlated with hospital costs. With a Spearman R of 1 and related R2 of 0.9436, scores of the 6 Aristotle comprehensive levels correlated best. Mean hospital reimbursement was 26,412 +/- 17,962 Euros. Compensation was higher than expenses for patients in comprehensive levels 1 to 3, but much lower for those in levels 4 to 6. CONCLUSIONS: Aristotle comprehensive complexity scores were highly correlated with hospital costs. The Aristotle score could be used as a scale to establish the correct reimbursement after congenital heart surgery.


Asunto(s)
Procedimientos Quirúrgicos Cardíacos/economía , Cardiopatías Congénitas/economía , Cardiopatías Congénitas/cirugía , Costos de Hospital , Reembolso de Seguro de Salud/economía , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Procedimientos Quirúrgicos Cardíacos/mortalidad , Cuidados Críticos/economía , Alemania , Cardiopatías Congénitas/mortalidad , Mortalidad Hospitalaria , Humanos , Lactante , Recién Nacido , Pacientes Internos , Tiempo de Internación/economía , Modelos Económicos , Respiración Artificial/economía , Medición de Riesgo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
14.
Hum Mutat ; 30(8): 1183-8, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19431183

RESUMEN

To assist in distinguishing disease-causing mutations from nonpathogenic polymorphisms, we developed an objective algorithm to calculate an "estimate of pathogenic probability" (EPP) based on the prevalence of a specific variation, its segregation within families, and its predicted effects on protein structure. Eleven missense variations in the RPE65 gene were evaluated in patients with Leber congenital amaurosis (LCA) using the EPP algorithm. The accuracy of the EPP algorithm was evaluated using a cell-culture assay of RPE65-isomerase activity The variations were engineered into plasmids containing a human RPE65 cDNA and the retinoid isomerase activity of each variant was determined in cultured cells. The EPP algorithm predicted eight substitution mutations to be disease-causing variants. The isomerase catalytic activities of these RPE65 variants were all less than 6% of wild-type. In contrast, the EPP algorithm predicted the other three substitutions to be non-disease-causing, with isomerase activities of 68%, 127%, and 110% of wild-type, respectively. We observed complete concordance between the predicted pathogenicities of missense variations in the RPE65 gene and retinoid isomerase activities measured in a functional assay. These results suggest that the EPP algorithm may be useful to evaluate the pathogenicity of missense variations in other disease genes where functional assays are not available.


Asunto(s)
Proteínas Portadoras/genética , Proteínas del Ojo/genética , Mutación Missense , Algoritmos , Secuencia de Aminoácidos , Secuencia de Bases , Biocatálisis , Proteínas Portadoras/química , Proteínas Portadoras/fisiología , Línea Celular , Cartilla de ADN , ADN Complementario , Proteínas del Ojo/química , Proteínas del Ojo/fisiología , Femenino , Humanos , Masculino , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Linaje , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , cis-trans-Isomerasas
15.
Thorac Cardiovasc Surg ; 56(7): 401-5, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18810697

RESUMEN

BACKGROUND: Can Contegra grafts withstand high pressure? METHODS: The function of Contegra grafts implanted after unifocalization of major aortopulmonary collateral arteries (MAPCAs) in 10 patients was evaluated. Median age at repair was 194 days and two conduit sizes were used: 12 mm (n = 8) and 14 mm (n = 2). Echocardiography and heart catheterization findings were reviewed. RESULTS: Two patients died: one early after repair, one late. Death was not graft related. The median duration of observation for survivors was 31 (range 4 - 42) months. The postoperative right ventricular/left ventricular pressure ratio was greater than 75 % in 9 patients. High pressures persisted in 6 survivors. Seven patients underwent interventional dilatation/stenting of pulmonary arteries on 19 occasions. No obstruction was detected in the conduit. Graft valve regurgitation increased in 5 patients, but never exceeded grade 2 (n = 4). Freedom from reoperation for conduit dysfunction/failure was 100 % at month 42. CONCLUSION: At mid-term follow-up, the Contegra grafts withstood high pressure without significant dysfunction or aneurysmal dilatation requiring surgery. Contegra appears to be an acceptable alternative to the aortic homograft for use after unifocalization of MAPCAs in infancy.


Asunto(s)
Bioprótesis , Implantación de Prótesis Vascular/instrumentación , Prótesis Vascular , Implantación de Prótesis de Válvulas Cardíacas/instrumentación , Prótesis Valvulares Cardíacas , Venas Yugulares/trasplante , Arteria Pulmonar/cirugía , Anastomosis Quirúrgica , Animales , Presión Sanguínea , Implantación de Prótesis Vascular/efectos adversos , Bovinos , Preescolar , Implantación de Prótesis de Válvulas Cardíacas/efectos adversos , Humanos , Lactante , Diseño de Prótesis , Falla de Prótesis , Arteria Pulmonar/fisiopatología , Reoperación , Factores de Tiempo , Resultado del Tratamiento , Presión Ventricular
16.
HNO ; 54(12): 943-6, 2006 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-16622695

RESUMEN

BACKGROUND: The goal of this study was to evaluate the effects of a fibrin gel on the healing of tympanic membrane perforation in rats. METHODS: Prolonged tympanic membrane perforations in 12 rats were created by application of mitomycin C to the intact tympanic membranes followed by bilateral myringotomy. Repeated applications of a fibrin gel to the perforation site of one tympanic membrane were performed in each animal. Tympanic membranes were observed for a total of 8 weeks. RESULTS: One perforation in each group was already patent at the end of the observation period. The mean healing period of the remaining tympanic membranes was found to be 16.7 days in the fibrin gel group and 19.6 days in the control group. CONCLUSION: A fibrin sheet does not seem to promote the wound healing process of tympanic membranes. However, the sheet might serve as a drug-delivery system for growth factors in the treatment of tympanic membrane perforations, because of its biocompatibility.


Asunto(s)
Modelos Animales de Enfermedad , Adhesivo de Tejido de Fibrina/administración & dosificación , Perforación de la Membrana Timpánica/tratamiento farmacológico , Cicatrización de Heridas/efectos de los fármacos , Animales , Geles/administración & dosificación , Ratas , Adhesivos Tisulares/administración & dosificación , Resultado del Tratamiento , Perforación de la Membrana Timpánica/diagnóstico
17.
HNO ; 53(6): 539-42, 544-5, 2005 Jun.
Artículo en Alemán | MEDLINE | ID: mdl-15316628

RESUMEN

BACKGROUND: The aim of this study was to evaluate the effects of an alginate matrix releasing epidermal growth factor on healing after acute tympanic membrane perforation in rats. METHOD: A total of 20 male rats were divided into two groups. In each animal, a randomly chosen tympanic membrane was perforated by heat. A piece of alginate matrix (control group) or alginate matrix loaded with 0.25 microg epidermal growth factor (EGF group) was then placed on the perforation. The rat ears were examined after days 3, 6, 9, and 14 and every week thereafter for a total of 11 weeks. Each matrix was removed on day 9. To examine the status of the tympanic membranes on day 14, one randomly chosen membrane from each group was histopathologically examined. RESULTS: By day 6, complete closure of the tympanic membrane perforation was achieved in 56% of the EGF group, whereas it was achieved in only 10% in the control group. By day 14, all tympanic membrane perforations were closed in both groups. There were no complications and no significant differences in the histopathologic parameters between the EGF group and the control group. CONCLUSION: An alginate matrix seems to be a useful EGF-delivery system to the tympanic membrane.


Asunto(s)
Alginatos/química , Portadores de Fármacos/química , Implantes de Medicamentos/administración & dosificación , Factor de Crecimiento Epidérmico/administración & dosificación , Factor de Crecimiento Epidérmico/química , Perforación de la Membrana Timpánica/tratamiento farmacológico , Cicatrización de Heridas/efectos de los fármacos , Administración Tópica , Animales , Materiales Biocompatibles/administración & dosificación , Materiales Biocompatibles/química , Ácido Glucurónico/química , Ácidos Hexurónicos/química , Masculino , Ensayo de Materiales , Membranas Artificiales , Ratas , Resultado del Tratamiento , Perforación de la Membrana Timpánica/patología
18.
Urologe A ; 44(1): 51-6, 2005 Jan.
Artículo en Alemán | MEDLINE | ID: mdl-15602650
19.
Br J Anaesth ; 89(3): 398-404, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12402717

RESUMEN

BACKGROUND: This retrospective study analysed the effects of preoperative and intraoperative factors on the occurrence of inotropic support after cardiopulmonary bypass (CPB). METHODS: The data sets of 1471 adult patients having received elective cardiac surgery with CPB were recorded using an online anaesthesia record-keeping system. Patients were judged to have required inotropic drug support if they had received one or a combination of the positive inotropic drugs, epinephrine, dobutamine and enoximone. The effects of age, height, weight, body mass index, gender, chronic heart failure, documented preoperative myocardial infarction, left main coronary artery disease, preoperative history of hypertension, chronic renal failure, diabetes mellitus, chronic obstructive pulmonary disease (COPD), preoperative medical treatment, type of surgical procedure, duration of CPB, duration of aortic clamping and reperfusion time were analysed by logistic regression for predictive power of the need for positive inotropic drugs. RESULTS: Of the patients, 32.4% received positive inotropic drugs in the operating theatre after weaning from CPB. The overall 30-day mortality was 2.2%. Of non-survivors, 81.8% received inotropes compared with 18.2% of survivors (P < 0.01). The numbers of previous myocardial infarctions (odds ratio (OR), 2.01), congestive heart failures New York Heart Association class > 2 (OR, 1.85), COPD (OR, 1.85) and age > 65 yr (OR, 1.62), aortic cross clamping time of > 90 min (OR, 2.32) and coronary artery bypass surgery (OR, 0.43) all represented influential factors within the logistic regression model. CONCLUSION: The knowledge of these risk factors should be useful in increasing the anaesthetist's vigilance in those patients most at risk for inotropic support and in providing for more timely therapeutic intervention and optimizing anaesthesia management.


Asunto(s)
Anestesia/métodos , Puente Cardiopulmonar , Cardiotónicos/uso terapéutico , Dobutamina/uso terapéutico , Enoximona/uso terapéutico , Epinefrina/uso terapéutico , Anciano , Femenino , Insuficiencia Cardíaca/complicaciones , Humanos , Masculino , Sistemas de Registros Médicos Computarizados , Persona de Mediana Edad , Infarto del Miocardio/complicaciones , Cuidados Preoperatorios , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA